APP, amyloid beta precursor protein, 351

N. diseases: 485; N. variants: 114
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0233514
Disease: Abnormal behavior
Abnormal behavior
0.200 Biomarker phenotype BEFREE A striking observation was that astrocytes associated with cerebral vessels laden with Aβ or associated with Aβ plaques showed increased reactivity in APP/PS1 mice lacking apoA-I.No behavioral changes were observed. 31084613 2019
CUI: C0233514
Disease: Abnormal behavior
Abnormal behavior
0.200 Biomarker phenotype BEFREE Behavioral Changes and Hippocampus Glucose Metabolism in APP/PS1 Transgenic Mice via Electro-acupuncture at Governor Vessel Acupoints. 28174534 2017
CUI: C0233514
Disease: Abnormal behavior
Abnormal behavior
0.200 Biomarker phenotype BEFREE This study systematically characterized changes in behavioral abnormalities in APP/PS1 transgenic mice. 28191738 2017
CUI: C0233514
Disease: Abnormal behavior
Abnormal behavior
0.200 AlteredExpression phenotype BEFREE Overexpression of Parkin in APP/PS1 transgenic mice restored activity-dependent synaptic plasticity and rescued behavioral abnormalities. 24105468 2014
CUI: C0233514
Disease: Abnormal behavior
Abnormal behavior
0.200 AlteredExpression phenotype BEFREE Our results showed that the transplantation of PD-MSCs into Aβ1-42-infused mice significantly improved cognitive impairment, and behavioral changes attenuated the expression of APP, BACE1, and Aβ, as well as the activity of β-secretase and γ-secretase. 24336078 2013
CUI: C0233514
Disease: Abnormal behavior
Abnormal behavior
0.200 Biomarker phenotype BEFREE These studies provide solid evidence that EE is a useful intervention to ameliorate behavioral changes and AD pathology in HFD-induced aggravation of AD symptoms in APP transgenic mice. 22197104 2012
CUI: C0233514
Disease: Abnormal behavior
Abnormal behavior
0.200 GeneticVariation phenotype BEFREE The London APP mutation (Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimer's disease. 20523046 2010
CUI: C0233514
Disease: Abnormal behavior
Abnormal behavior
0.200 Biomarker phenotype BEFREE These findings demonstrated that the behavioral abnormalities of the APP-PS1 mice started at about 30 weeks of age and that the hippocampus and temporal cortex were the most sensitive regions during early-stage AD. 20307581 2010
CUI: C0233514
Disease: Abnormal behavior
Abnormal behavior
0.200 Biomarker phenotype BEFREE These results suggest that Asp-664 plays a critical role in the generation of Alzheimer-related pathophysiological and behavioral changes in human APP transgenic mice, possibly as a cleavage site or via protein-protein interactions. 16641106 2006
CUI: C0233514
Disease: Abnormal behavior
Abnormal behavior
0.200 Biomarker phenotype BEFREE Reduction in mitochondrial superoxide dismutase modulates Alzheimer's disease-like pathology and accelerates the onset of behavioral changes in human amyloid precursor protein transgenic mice. 16687508 2006
CUI: C0233514
Disease: Abnormal behavior
Abnormal behavior
0.200 AlteredExpression phenotype BEFREE The hypoactivity and the spatial learning deficit were associated with higher cytochrome oxidase activity seen in thalamic nuclei, indicating that altered regional brain metabolism caused by betaAPP transgene expression may be responsible for the behavioral changes. 12559409 2002
CUI: C0233514
Disease: Abnormal behavior
Abnormal behavior
0.200 Biomarker phenotype BEFREE Moreover, some behavioral disturbances displayed by APP mice lacking apoE are even more pronounced than those of APP mice expressing apoE. 10718322 2000
CUI: C0233514
Disease: Abnormal behavior
Abnormal behavior
0.200 GeneticVariation phenotype BEFREE These transgenic mice showed the same early behavioral disturbances and defects and increased premature death as the APP/London (APP V717I), APP/Swedish (K670N, M671L), and other APP transgenic mice described previously. 10671319 2000
CUI: C0233514
Disease: Abnormal behavior
Abnormal behavior
0.200 Biomarker phenotype HPO